经腔静脉内漏栓塞新技术及结局
该回顾性研究纳入2019年3月至2021年6月接受经腔静脉栓塞的12例患者,采用0.014英寸重型头端导丝配合持续电流电灼建立下腔静脉至主动脉瘤囊通道,全部患者成功建立通道,2/12(16%)目标血管实现选择性插管,术后30天4/12(33.3%)患者存在持续内漏。
要点
- 经腔静脉栓塞采用电灼导丝技术建立下腔静脉至主动脉瘤囊通道,12例全部成功。
- 仅2/12(16%)目标血管实现选择性插管,其余10/12行非选择性栓塞。
- 术后30天4/12(33.3%)存在持续内漏,3/12(25%)瘤囊增大>5 mm。
核心结论
- 经腔静脉栓塞是经动脉或经腰途径失败后治疗内漏的辅助技术。
- 电灼0.014英寸慢性完全闭塞导丝经腔静脉入路至主动脉瘤囊行内漏栓塞在所有病例中均可成功,无显著急性并发症或死亡。
- 经腔静脉途径仍受限于导管和微导管进入流出血管的能力,导致持续内漏和最终需要移植物取出。
研究设计与样本
- 回顾性综述,纳入在三级转诊中心接受经腔静脉栓塞的所有患者。
- 2019年3月至2021年6月共识别12例患者接受新型经腔静脉主动脉瘤囊入路。
- 使用0.014英寸重型头端导丝和持续电流电灼在下腔静脉与主动脉瘤囊之间建立连接。
- 随后对內漏流出血管行弹簧圈或液体栓塞剂选择性栓塞;无法选择性栓塞时向瘤囊注入液体栓塞剂诱导血栓形成。
主要发现
- 12例患者平均年龄79.2 ± 6.2岁,10/12(83.3%)为男性,合并症率高。
- 经腔静脉进入主动脉瘤囊全部成功,2/12(16%)目标血管实现选择性插管,两例均使用可解脱弹簧圈和液体栓塞剂栓塞。
- 其余10/12例使用液体栓塞剂和血栓形成剂行非选择性栓塞。
- 围手术期并发症为轻微出血1/12(8.3%),2例因背痛在重症监护室观察。
- 术后30天影像学检查发现4/12(33.3%)患者存在持续内漏,3/12(25%)患者经腔静脉栓塞后瘤囊增大>5 mm。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Strategies for embolization of type 2 endoleaks include translumbar, transgraft, transarterial, and transcaval approaches. The transcaval approach is limited by an inconsistent ability to access the aortic sac and the risk of puncturing and damaging the endograft or adjacent structures. We describe a novel technique for caval to aortic aneurysm sac access and report early outcomes. METHODS: A retrospective review of all patients who underwent transcaval embolization (TCE) at a tertiary referral center. From March 2019 to June 2021, 12 patients were identified to have undergone a novel approach to transcaval aortic sac access using a 0.014″ heavy weight tip wire guide and continuous current electrocautery to create the connection between the inferior vena cava and aortic aneurysm sac. The endoleak outflow vessel is then selectively embolized with coils or liquid embolic agents. When selective embolization was not possible, the aneurysm sac was instilled with liquid embolic agents to induce thrombosis. RESULTS: Twelve patients underwent transcaval embolization using this method over the 3-year period. The average patient age was 79.2 ± 6.2 years and 10/12 (83.3%) were male. A high rate of comorbidities was noted in the cohort. Transcaval access into the aortic sac was achieved in all patients, while selective cannulation of outflow vessels was accomplished in 2/12 (16%) target vessels. Of these, both cases had vessels embolized using detachable coils and liquid embolic agents. Nonselective embolization was performed using liquid embolic and thrombotic agents in the other 10/12 cases. There was one perioperative complication of minor bleeding (1/12, 8.3%). Two patients were observed in intensive care unit for back pain. A persistent endoleak was identified on postoperative imaging performed at 30 days in 4/12 (33.3%) patients. Sac enlargement > 5 mm following TCE was observed in 3/12 (25%) patients. Three patients underwent open conversion with endovascular aneurysm repair explant. One patient was explanted at 1 month after failure to embolize the endoleak flow channel using TCE. A second was explanted for persistent endoleak found to be a Type IIIb with aortic diameter growth > 5 mm at 15-month follow-up. The third explant was performed for aortic sac infection at 4 months postprocedure without endoleak. CONCLUSIONS: TCE is an adjunctive technique to treat endoleaks in patients who have either failed transarterial or translumbar access. An electrified 0.014″ chronic total occlusion wire technique for transcaval access to the aortic sac for endoleak embolization can be successful in all cases without significant acute morbidity or mortality. The transcaval approach is still limited by ability to steer catheters and microcatheters into the outflow vessels with a resultant persistent endoleak and eventual need for explant.
引用
- Van Sickler AP, Smith AH, Ellis RC, et al. A Novel Technique and Outcomes for Transcaval Endoleak Embolization. Ann Vasc Surg. 2023. PMID: 36641088. doi:10.1016/j.avsg.2023.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。